BioSpace News Archive

The Supervisory Board of biopharmaceutical Company MOLOGEN AG appointed Dr Ignacio Faus as Member of the Executive Board and new Chief Executive Officer (CEO) of MOLOGEN AG with effect from August 1, 2018.

Prices for pharmaceuticals are projected to rise by 4.92 percent in 2019, down from an estimated 7.61 percent in 2018

Sage Therapeutics today announced that the Company will present at the Canaccord 38th Annual Growth Conference on Wednesday, August 8, 2018 at 11:00 A.M. ET in Boston, MA.

Promising Technology Platform to Potentially Deliver Therapies to Treat a Broad Spectrum of Ophthalmic Diseases.

LivaNova PLC reported results for the quarter ended June 30, 2018.

To safeguard the legitimate interests of Sinovac Biotech Ltd. and its shareholders, the Current Board hereby makes the following statements:

United Therapeutics Corporation announced its financial results for the quarter ended June 30, 2018.

Ardelyx, Inc. announced that it plans to report its second quarter 2018 financial results after market close on Tuesday, August 7, 2018. Management will host a conference call and webcast that afternoon at 4:30 p.m. ET to discuss the results and other business updates.

Reports revenue growth of 14% on a reported basis and 12% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 15% reported and 13% organic

Phico Therapeutics Ltd (‘Phico’), a biotechnology company developing a novel platform technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, today announced that it had been awarded significant funding to support the manufacturing development of its intravenous antibiotic, SASPject PT3.8.